Trial Profile
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Comparability Study To Assess The Pharmacokinetics Of Pf-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 03 Jun 2016 Status changed from recruiting to completed.
- 17 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.